about
Recent developments in drug discovery for leishmaniasis and human African trypanosomiasisStructures of Substrate- and Inhibitor-Bound Adenosine Deaminase from a Human Malaria Parasite Show a Dramatic Conformational Change and Shed Light on Drug SelectivityCrystal structure of the aspartyl-tRNA synthetase from Entamoeba histolyticaToxoplasma gondii calcium-dependent protein kinase 1 is a target for selective kinase inhibitorsThe Double-Length Tyrosyl-tRNA Synthetase from the Eukaryote Leishmania major Forms an Intrinsically Asymmetric Pseudo-DimerDistinct States of Methionyl-tRNA Synthetase Indicate Inhibitor Binding by Conformational SelectionStructure of the prolyl-tRNA synthetase from the eukaryotic pathogenGiardia lambliaStructures of Trypanosoma brucei methionyl-tRNA synthetase with urea-based inhibitors provide guidance for drug design against sleeping sickness5-Fluoroimidazo[4,5-b]pyridine Is a Privileged Fragment That Conveys Bioavailability to Potent Trypanosomal Methionyl-tRNA Synthetase InhibitorsStructure of a ribulose 5-phosphate 3-epimerase from Plasmodium falciparumSynergy testing of FDA-approved drugs identifies potent drug combinations against Trypanosoma cruziBrucella melitensis Methionyl-tRNA-Synthetase (MetRS), a Potential Drug Target for BrucellosisProteasome inhibition for treatment of leishmaniasis, Chagas disease and sleeping sicknessRecent highlights in anti-protozoan drug development and resistance research.Potent, Plasmodium-selective farnesyltransferase inhibitors that arrest the growth of malaria parasites: structure-activity relationships of ethylenediamine-analogue scaffolds and homology model validation.Buffer optimization of thermal melt assays of Plasmodium proteins for detection of small-molecule ligandsSecond generation analogues of the cancer drug clinical candidate tipifarnib for anti-Chagas disease drug discovery.Selective inhibitors of methionyl-tRNA synthetase have potent activity against Trypanosoma brucei Infection in MiceIdentification of potent inhibitors of the Trypanosoma brucei methionyl-tRNA synthetase via high-throughput orthogonal screening.A binding hotspot in Trypanosoma cruzi histidyl-tRNA synthetase revealed by fragment-based crystallographic cocktail screens.Inhibitors of methionyl-tRNA synthetase have potent activity against Giardia intestinalis trophozoites.Bioisosteric transformations and permutations in the triazolopyrimidine scaffold to identify the minimum pharmacophore required for inhibitory activity against Plasmodium falciparum dihydroorotate dehydrogenaseFrom Cells to Mice to Target: Characterization of NEU-1053 (SB-443342) and Its Analogues for Treatment of Human African Trypanosomiasis.Urea-based inhibitors of Trypanosoma brucei methionyl-tRNA synthetase: selectivity and in vivo characterization.Structure of ribose 5-phosphate isomerase from Plasmodium falciparumCrystal structures and proposed structural/functional classification of three protozoan proteins from the isochorismatase superfamily.Advances in Chagas disease drug development: 2009-2010Induced resistance to methionyl-tRNA synthetase inhibitors in Trypanosoma brucei is due to overexpression of the target.Altered sterol profile induced in Leishmania amazonensis by a natural dihydroxymethoxylated chalcone.Sterol 14-demethylase inhibitors for Trypanosoma cruzi infections.Structurally simple inhibitors of lanosterol 14alpha-demethylase are efficacious in a rodent model of acute Chagas disease.Urea Derivatives of 2-Aryl-benzothiazol-5-amines: A New Class of Potential Drugs for Human African Trypanosomiasis.Optimization of a binding fragment targeting the "enlarged methionine pocket" leads to potent Trypanosoma brucei methionyl-tRNA synthetase inhibitors.Leishmania donovani tyrosyl-tRNA synthetase structure in complex with a tyrosyl adenylate analog and comparisons with human and protozoan counterparts.Experimental chemotherapy and approaches to drug discovery for Trypanosoma cruzi infection.Development of methionyl-tRNA synthetase inhibitors as antibiotics for Gram-positive bacterial infections.New Class of Antitrypanosomal Agents Based on Imidazopyridines.Structure-guided design of novel Trypanosoma brucei Methionyl-tRNA synthetase inhibitors.Recent Developments in Sterol 14-demethylase Inhibitors for Chagas Disease.Prediction of protein crystallization outcome using a hybrid method
P50
Q27011766-3802A3DC-6556-4E2E-9976-A964094A2EA6Q27651039-46EE3C61-FD3D-4F49-8FA4-A0F576634C5FQ27658015-8291ED02-B684-4DE3-808B-84988481ADAFQ27661190-4B315DC0-AA4C-4FB8-B944-863DFA516271Q27667299-FBD7DE56-9BF9-4468-928B-E35F09A20B26Q27671580-8447A6F6-08C5-4E4F-9050-33D214098AC6Q27671923-0A8323A1-A5A9-4D80-A7EA-FD54E54AF752Q27683462-1C284A71-EA8E-414B-95B8-C4EE70644CEBQ27728066-F4584CA4-DD34-46A2-B24B-A842B726CA61Q28283187-EFE03204-64FA-4D6F-97FF-0CF4F86F25D9Q28540817-304F169F-5C34-4BCA-B67F-23FEAE4EE2AEQ28553414-32EC3907-6370-4D8E-9C3A-EA01546DB486Q28817181-98F0E5C6-1B1E-456C-8F6B-0C22296FC6BBQ30414810-CEC825C9-FFF9-4A1F-A381-29EB357FA921Q30498356-AD658788-33BC-4750-AADE-155B473A4418Q33453099-B9594BA0-A9DE-4C76-A983-9C3B68707BCAQ33879398-462809D8-C42E-48B7-B5CC-8BE90D4F689FQ34933050-AB88E821-0A64-4616-9A32-E8308B50FC6BQ35230791-371CF321-2CB0-491D-ABFC-05584223AD96Q35739221-11793912-E2CC-44D5-8ACA-B9ECF7BEEE45Q36158335-ED58FC80-1299-46CD-9E14-EFA4F0F00B51Q36247004-3340684E-18EE-4438-9D44-66C516853493Q36256694-BE283150-B6B0-4BAF-A61B-24554FDE75AFQ36344515-317E969B-C392-49A1-B26E-C2E4C7A20D03Q36417405-0992EE27-703D-4EEB-BB73-AF02FC250786Q36476548-712660EF-060E-46F9-B804-F48FFC541C74Q36702159-ABDE8F49-0412-4789-AC72-CD5217241366Q36969804-8B3B23B0-6360-4CA2-BED8-524B0D0F70C8Q37092398-5C7856C8-713A-4246-B3EF-59393C3B793AQ37118721-1D63CD9A-1DB5-4A83-8A16-10894739A72DQ37408442-FB7F7B99-7335-409E-8809-FDD1F89955A8Q37716060-2AA2D759-A1C4-46D6-B5A2-DB4EB61162A3Q38705156-36B4E556-A42E-4C57-B246-EAA0729DF2E9Q38894760-A4616A07-E687-4D3F-A66D-DFDC1F55F43EQ39494288-77378688-79F3-43B5-BCD3-A7371B8FB578Q40077119-CC1109D3-D286-4861-AF21-2C0D268840EEQ40121339-CEBF5633-C03F-48B8-A88E-AFB5432BF24CQ40481558-325B2DBB-07BB-4C2F-BFB7-1E4D595A6282Q41955446-0735CCEF-CE80-4DB4-92A2-22F9813535D8Q42113472-D2CAA811-258B-4BC9-9DDF-B3CB1AA5EDAB
P50
description
investigador
@es
researcher
@en
wetenschapper
@nl
name
Frederick S Buckner
@en
Frederick S Buckner
@nl
type
label
Frederick S Buckner
@en
Frederick S Buckner
@nl
prefLabel
Frederick S Buckner
@en
Frederick S Buckner
@nl
P31
P496
0000-0001-7796-6477